The Food and Drug Administration recently approved the FreeStyle Libre Pro system, a continuous glucose monitoring system developed by Abbott Park, Ill.-based Abbott. To use the system, clinicians ...

Abbott has announced that the US Food and Drug Administration (FDA) has approved the FreeStyle Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to ...

Abbott has received FDA Clearance for its FreeStyle Libre Pro system, a key milestone in bringing the company's unique take on the continuous glucose monitor to the United States. In Europe, where the ...

The Freestyle Libre 14 day is now the longest-lasting self-applied continuous glucose sensing technology available and allows the used to wear the sensor for up to 14 days with high accuracy. ABBOTT ...

The FreeStyle Libre 3 glucose monitoring system (Abbott) has been granted a CE mark for use by people with diabetes in the countries of the European Union (EU). The next-generation FreeStyle Libre 3 ...

A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional ...

The use of the affected product may cause serious adverse health consequences. There have been two reported injuries. Abbott announced the U.S. availability of Lingo, the company's first continuous ...

The issue affected about 3 million Libre 3 and Libre 3 Plus sensors in the U.S. and globally Abbott has received reports of 736 serious health problems (57 in the U.S.) and seven deaths (none in the U ...

Collaboration brings together FreeStyle Libre ® Systems, the world's leading continuous glucose monitoring technology (CGM) 1 with Epic, a healthcare software company, to streamline access to CGM data ...

Credit: Abbott. The FreeStyle Libre 3 reader is a standalone, small handheld device that displays real-time glucose readings. The Food and Drug Administration (FDA) has cleared a standalone reader to ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology 1, today announced that it has entered a ...